The Drugs Controller General of India (DGCI) on Friday approved the emergency use for Zydus Cadila’s Pegylated Interferon alpha-2b ‘Virafin’ for treating moderate COVID-19 infection for adults.
Zydus Cadila announced that it has received emergency use approval from DCGI to use Virafin for the treatment of moderate COVID-19 infections.
As per the report, a single-dose subcutaneous regimen of the drug will make the treatment of COVID-19 more convenient.
The company had said that if administered early on during COVID-19, Virafin may help patients recover faster and avoid much of the complications. It will be available on the prescription of a medical specialist.
